New hope for rare inflammatory disease: canakinumab shows promise in japanese study

NCT ID NCT04717635

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 01, 2026 · Last updated May 16, 2026 · Updated 7 times

Summary

This study tested a drug called canakinumab in 14 Japanese adults with Adult-Onset Still's Disease, a rare inflammatory condition. Participants received injections every 4 weeks for at least 48 weeks. The goal was to see if the drug could reduce joint pain, fever, and inflammation, and help lower the need for steroids. Results supported the drug's approval in Japan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT ONSET STILL'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Chiba, Chiba, 260 8677, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 0608648, Japan
Novartis Investigative Site

Yokohama, Kanagawa-ku, 236-0004, Japan
Novartis Investigative Site

Iruma-gun, Saitama, 3500495, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138655, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 1048560, Japan
Novartis Investigative Site

Mitaka, Tokyo, 181-8611, Japan
Novartis Investigative Site

Shinjuku-ku, Tokyo, 1608582, Japan
Novartis Investigative Site

Ishikawa, 9208641, Japan

Conditions

Explore the condition pages connected to this study.

ADULT ONSET STILL'S DISEASE